Gene · 6752
Papers3,968
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 3,968
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Case report: Indocyanine green fluorescence-guided imaging in laparoscope, a more sensitive detection technique of lateral lymph nodes metastases from rectal neuroendocrine tumors. | Front Oncol | 2022 | 36591455 | PubTator, text mining | PubMed |
| Targeted alpha therapy for glioblastoma. | Front Med (Lausanne) | 2022 | 36590948 | PubTator, text mining | PubMed |
| Inflammatory myofibroblastic tumor of the central nervous system: A case report. | World J Clin Cases | 2022 | 36579095 | PubTator, text mining | PubMed |
| A personal acquisition time regimen of 68Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study. | Cancer Imaging | 2022 | 36578034 | PubTator, text mining | PubMed |
| A rare lymphoplasmacyte-rich meningioma involving the dura of the skull base and cervical spinal cord: A case report. | Transl Neurosci | 2022 | 36570486 | PubTator, text mining | PubMed |
| Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. | Front Med (Lausanne) | 2022 | 36569154 | PubTator, text mining | PubMed |
| Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [153Sm]Sm-DOTA-TATE. | Pharmaceutics | 2022 | 36559060 | PubTator, text mining | PubMed |
| Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling. | Int J Mol Sci | 2022 | 36555512 | PubTator, text mining | PubMed |
Aberrant Methylation of Somatostatin Receptor 2 Gene Is Initiated in Aged Gastric Mucosa Infected with Helicobacter pylori and Consequential Gene Silencing Is Associated with Establishment of Inflammatory Microenvironment In Vitro Study. | Cancers (Basel) | 2022 | 36551669 | PubTator, text mining | PubMed |
| Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors. | Cancers (Basel) | 2022 | 36551599 | PubTator, text mining | PubMed |
| Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT. | Cancers (Basel) | 2022 | 36551525 | PubTator, text mining | PubMed |
| Coexistence of primary pulmonary meningioma and metastatic papillary renal cell carcinoma of the lung: A rare case report with review of the literature. | Medicine (Baltimore) | 2022 | 36550861 | PubTator, text mining | PubMed |
| Individualized medical treatment options in Cushing disease. | Front Endocrinol (Lausanne) | 2022 | 36531477 | PubTator, text mining | PubMed |
Combination of transsphenoidal endoscopic surgery and presurgical somatostatin analogs in thyrotropin (TSH)-secreting pituitary adenomas: Treatment outcome and long-term remission at a single pituitary center. | Front Endocrinol (Lausanne) | 2022 | 36518240 | PubTator, text mining | PubMed |
| Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report. | Eur J Hybrid Imaging | 2022 | 36510100 | PubTator, text mining | PubMed |
| Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. | Cancers (Basel) | 2022 | 36497404 | PubTator, text mining | PubMed |
| Clinical Management of Supratentorial Non-Skull Base Meningiomas. | Cancers (Basel) | 2022 | 36497370 | PubTator, text mining | PubMed |
| A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients. | Cancers (Basel) | 2022 | 36497273 | PubTator, text mining | PubMed |
| Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly. | Cells | 2022 | 36497102 | PubTator, text mining | PubMed |
| Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective. | Front Oncol | 2022 | 36483036 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6752/papers?page=40